TRAW (Traws Pharma) Short Interest


TRAW Traws Pharma Inc TRAW
49 GF Score
Price $0.83
GF Value $12.92
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TRAW vs CVM, CRIS, QNCX: Short Interest Comparison

For the Biotechnology subindustry, Traws Pharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Traws Pharma Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Short Interest falls into.


TRAW
49GF Score
Traws Pharma Inc TRAW
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.83 is trading 93.6% below its estimated GF Value™ of $12.92. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • Short Interest:
  • GF Value™: $12.92 vs. price of $0.83 (93.6% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
49GF Score

Get the complete analysis for TRAW

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.83
Price
$12.92
GF Value